Earnings call transcript: Novo Nordisk Q2 2025 shows strong growth

Novo Nordisk reported robust H1 2024 financial results, with revenue growing 18% and operating profit increasing 29% at constant exchange rates, driven by strong product performance and expanded patient reach. However, the company revised its full-year sales growth guidance to 8-14% and operating profit to 10-16%, attributing the adjustment to a lower U.S. volume outlook for Ozempic and Wegovy, partly due to the persistent compounding market which it is actively combating. Strategically, Novo Nordisk is preparing for the early 2026 U.S. launch of oral semaglutide for obesity, which demonstrated comparable efficacy to injectables, while continuing significant capital expenditures to expand manufacturing capacity and address competitive pressures and potential loss of exclusivity in 2026.

Analysis

Novo Nordisk reported strong performance for the first half of 2024, with revenue climbing 18% and operating profit rising 29% at constant exchange rates, supported by a DKK 34 billion free cash flow despite significant capital investment. However, the company has lowered its full-year sales growth guidance to 8-14%, citing a weaker U.S. volume outlook for its key obesity and diabetes drugs, Wegovy and Ozempic. This U.S. softness is influenced by intense competition from Eli Lilly and a persistent illegal compounding market, which Novo Nordisk estimates constitutes 30% of the market (~1 million patients) and is actively working to curtail through regulatory channels. Management notes early positive indicators from a strategic shift back to a weight-loss-focused marketing message for Wegovy, which has started to reverse a decline in new prescriptions (NBRx). Looking ahead, the company is heavily focused on future growth drivers, primarily the U.S. launch of oral semaglutide for obesity in early 2026, which is positioned as a best-in-class oral agent with efficacy comparable to injectables. Additional growth is expected from the upcoming NASH indication for Wegovy and continued expansion in international markets, which grew 19% in H1. While the company anticipates a manageable low single-digit top-line impact from loss of exclusivity in 2026, it is also nearing peak capital expenditure, which should improve financial flexibility after 2025.

Key Decisions for Investors

• Investors should closely monitor U.S. new prescription (NBRx) data for Wegovy to validate management's claim of a positive trend reversal, as near-term performance is contingent on successfully navigating the competitive U.S. landscape.
• The illegal compounding market represents a significant current headwind but also a potential upside catalyst; any successful regulatory or legal action by the FDA to curb illicit API imports could unlock substantial volume growth not currently factored into guidance.
• The early 2026 launch of oral semaglutide is a pivotal long-term catalyst, investors should assess its potential to expand the total addressable market for obesity treatment and defend market share against competitors.
• Consider the company's financial trajectory, as it is approaching peak capital expenditure which could enhance free cash flow generation post-2025, while the expected low single-digit revenue impact from 2026 loss of exclusivity appears contained by the pipeline's strength.